Literature DB >> 3170557

Substitution of cysteine for glycine within the carboxyl-terminal telopeptide of the alpha 1 chain of type I collagen produces mild osteogenesis imperfecta.

D H Cohn1, S Apone, D R Eyre, B J Starman, P Andreassen, H Charbonneau, A C Nicholls, F M Pope, P H Byers.   

Abstract

We have characterized a mutation that produces mild, dominantly inherited osteogenesis imperfecta. Half of the alpha 1 (I) chains of type I collagen synthesized by cells from an affected individual contain a cysteine residue in the 196-residue carboxyl-terminal cyanogen bromide peptide of the triple-helical domain (Steinmann, B., Nicholls, A., and Pope, F. M. (1986) J. Biol. Chem. 261, 8958-8964). Unexpectedly, sequence determined from a proteolytic fragment of the alpha 1 (I) chain derived from procollagen molecules synthesized in the presence of both [3H]proline and [35S]cysteine indicated that the cysteine is located at the third residue carboxyl-terminal to the triple-helical domain, normally a glycine. The nucleotide sequence of a fragment amplified from genomic DNA confirmed the location of the cysteine residue and showed that the mutation was a single nucleotide change in one COL1A1 allele. This represents a new class of mutations, point mutations outside the triple-helical domain of the chains of type I collagen, that produce the osteogenesis imperfecta phenotype.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3170557

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  12 in total

Review 1.  Osteogenesis imperfecta: translation of mutation to phenotype.

Authors:  P H Byers; G A Wallis; M C Willing
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

Review 2.  Skeletal dysplasias.

Authors:  Deborah Krakow
Journal:  Clin Perinatol       Date:  2015-04-08       Impact factor: 3.430

Review 3.  Application of the polymerase chain reaction to the diagnosis of human genetic disease.

Authors:  J Reiss; D N Cooper
Journal:  Hum Genet       Date:  1990-06       Impact factor: 4.132

Review 4.  Prenatal diagnosis and prevention of inherited abnormalities of collagen.

Authors:  F M Pope; S C Daw; P Narcisi; A R Richards; A C Nicholls
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

5.  Transgenic mouse model of the mild dominant form of osteogenesis imperfecta.

Authors:  J Bonadio; T L Saunders; E Tsai; S A Goldstein; J Morris-Wiman; L Brinkley; D F Dolan; R A Altschuler; J E Hawkins; J F Bateman
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

6.  Osteogenesis imperfecta type I is commonly due to a COL1A1 null allele of type I collagen.

Authors:  M C Willing; C J Pruchno; M Atkinson; P H Byers
Journal:  Am J Hum Genet       Date:  1992-09       Impact factor: 11.025

7.  Frameshift mutation near the 3' end of the COL1A1 gene of type I collagen predicts an elongated Pro alpha 1(I) chain and results in osteogenesis imperfecta type I.

Authors:  M C Willing; D H Cohn; P H Byers
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

8.  Substitution of cysteine for glycine at residue 415 of one allele of the alpha 1(I) chain of type I procollagen in type III/IV osteogenesis imperfecta.

Authors:  A C Nicholls; J Oliver; D V Renouf; M Keston; F M Pope
Journal:  J Med Genet       Date:  1991-11       Impact factor: 6.318

9.  Osteogenesis imperfecta type I: molecular heterogeneity for COL1A1 null alleles of type I collagen.

Authors:  M C Willing; S P Deschenes; D A Scott; P H Byers; R L Slayton; S H Pitts; H Arikat; E J Roberts
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

10.  An osteopenic nonfracture syndrome with features of mild osteogenesis imperfecta associated with the substitution of a cysteine for glycine at triple helix position 43 in the pro alpha 1(I) chain of type I collagen.

Authors:  J R Shapiro; M L Stover; V E Burn; M B McKinstry; A L Burshell; S D Chipman; D W Rowe
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.